Literature DB >> 7161779

Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon.

C G Kallenberg, E Vellenga, A A Wouda, T H The.   

Abstract

Circulating immune complexes (CIC), platelet activation and fibrinolytic activity were assessed in 133 patients with Raynaud's phenomenon (RP), 41 with primary RP, 73 with secondary RP and 19 with RP and minor symptoms of connective tissue disease (suspected secondary RP). Increased levels of CIC were found in secondary and suspected secondary RP. In those groups spontaneous platelet aggregation also was found, a percentage of which correlated with levels of CIC. In all groups elevated levels of beta-thromboglobulin, a platelet specific protein released during platelet activation, and decreased levels of alpha 2-antiplasmin, the main inhibitor of fibrinolysis, were found, together with hyperfibrinogenemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7161779

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Raynaud's phenomenon: epidemiology and risk factors.

Authors:  Liana Fraenkel
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 2.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

3.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

4.  Raynaud's disease.

Authors:  E C Burns; D B Dunger; M J Dillon
Journal:  Arch Dis Child       Date:  1985-06       Impact factor: 3.791

5.  Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations.

Authors:  R G Malia; M Greaves; L M Rowlands; A C Lawrence; A Hume; N R Rowell; J Moult; C M Holt; N Lindsey; P Hughes
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

6.  Plasma or serum from patients with systemic sclerosis alters behaviour of normal erythrocytes.

Authors:  I B Kovacs; M H Rustin; R H Thomas; C Ridler; S O Sowemimo-Coker; J D Kirby
Journal:  Ann Rheum Dis       Date:  1985-06       Impact factor: 19.103

7.  Decreased nailfold capillary density in Raynaud's phenomenon: a reflection of immunologically mediated local and systemic vascular disease?

Authors:  P M Houtman; C G Kallenberg; A A Wouda; T H The
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

8.  Platelet serotonin in systemic sclerosis.

Authors:  P S Klimiuk; A Grennan; C Weinkove; M I Jayson
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

9.  Abnormal platelet aggregation in patients with Raynaud's phenomenon.

Authors:  M L Biondi; B Marasini
Journal:  J Clin Pathol       Date:  1989-07       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.